Lutris Pharma to Present at the 16th Annual European Life Sciences CEO Forum in March

Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing dose limiting side effects, today announced that Antoni Ribas, M.D., Ph.D., Chairman and Founder of Lutris Pharma, will present a company overview, virtually, at the 16th Annual European Life Sciences CEO Forum on March 8, 2023.

The company will also host virtual one-on-one meetings with investors March 8-10, 2023. Interested parties can schedule a meeting using the online conference platform after registering at

An archived replay of the company’s presentation will be available after the event on the “Events and Presentations” section of the Lutris website at:

About Lutris Pharma

Lutris Pharma is a clinical stage biopharmaceutical company focused on improving anti-cancer therapy effectiveness and quality of life for patients who are being treated with EGFR (Epidermal Growth Factor Receptor) inhibitors or with radiation, where dermal toxicity often leads to a reduction of anti-cancer therapy compliance. The company aims to provide novel topical therapies in order to mitigate these side effects. Lutris Pharma’s lead asset, LUT014, a topical B-Raf Inhibitor, is a proprietary, first-in-class, small molecule currently in a phase 2 clinical trial in metastatic colorectal cancer patients with EGFR inhibitor induced acneiform lesions and has successfully completed a phase 1/2 study for the treatment of radiation-induced dermatitis in breast cancer patients. For more information, please visit

Written by Shantel

GlycoPath Appoints Kathy Phlegar as CEO

Co-founder and former CEO of Snow Software joins Netigate as Chairman to stimulate growth